Abstract Body

Background

Global HIV incidence remains high, with ~1.3 million new acquisitions in 2024. Of 40.8 million PLWH, an estimated 11 million had detectable HIV RNA: 48% were unaware of their status, 35% were aware but not on ART, and 16% were on ART but not suppressed. UNAIDS data from 2018–2024 show a stable ratio of ~1 HIV acquisition per 10 viremic PLWH.

Methods

We modeled ART, PrEP, and mixed scale-up scenarios needed to avert 1 million HIV acquisitions annually—the reduction required to reach <300,000 by 2030. Using UNAIDS data, we analyzed parallel declines in viremic PLWH and incidence, applying a simple ratio framework (1 acquisition per 10 viremic PLWH per year). We then modeled expanded PrEP coverage, assuming a conservative global number needed to treat (NNT) of 100 (PURPOSE 1 and 2 trials NNT = 41 and 42).

Results

Each 10 million additional PLWH achieving viral suppression through ART would prevent ~1 million HIV acquisitions annually. Alternatively, ~100 million people on effective PrEP would be needed. A mix is likely most realistic, for example, 5 million additional PLWH achieving suppression plus 50 million PrEP users could jointly avert ~1 million acquisitions annually. Current PrEP use globally remains far below this threshold: UNAIDS estimates 3.9 million oral PrEP users in 2024, far short of the 2025 target of 21.2 million. Declines in HIV incidence to date have been primarily driven by ART expansion, which grew from 7.7 million on ART in 2010 to 31.6 million in 2024, but still falls short of the 34 million target for 2025.

Conclusions

Achieving an additional 1 million annual reduction in HIV acquisitions will require expanded ART coverage (10 million more virally suppressed) and PrEP scale up (to ~100 million users), or a combination of both. The persistent ratio of 1 acquisition per 10 viremic PLWH highlights that ART roll-out (U=U) has driven declines to date, but closing the prevention gap will require integrating U=U with large-scale PrEP expansion. These findings underscore that the recently announced Global Fund and PEPFAR target of 2 million people on lenacapavir by 2028 is insufficient (20,000-50,000 infections averted annually–NNT range 40-100) relative to the scale needed. Without far more ambitious targets for long-acting PrEP, we risk missing the opportunity to achieve epidemic control by 2030.

Table or Figure